Field Trip Health Ltd. Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin Services

Field Trip plans to enters Oregon’s medicinal market for psilocybin-assisted psychotherapy.

Read more
Pure Extracts Technologies Corp. Commences Trading on the Canadian Securities Exchange (CSE)

Pure Extracts is now trading under the symbol “PULL”.

Read more
New Jersey Votes to Legalize Cannabis

Voters in New Jersey have approved the state’s adult-use cannabis legalization ballot question with overwhelming support, making it the 12th state to end cannabis prohibition.

Read more
Four More Ohio Cities Approve Marijuana Decriminalization Measures

Four more Ohio cities have adopted local measures to decriminalize marijuana.

Read more
Psychedelics Revolution Front-and-Center As Americans Prepare To Vote

On the eve of the U.S. election, psychedelic drugs are a high-profile election issue.

Read more
Pure Extracts Technologies Corp. to Commence Trading on the Canadian Securities Exchange (CSE)

Pure Extracts Corp. is an extraction specialist targeting the cannabis, psychedelics and functional mushrooms sectors and will trade on the CSE under the symbol “PULL”.

Read more
Federal marijuana reform prospects bright – provided the Senate flips, Biden wins

Tuesday’s general election could have huge implications for federal marijuana reform, but the biggest business impacts hinge on whether the U.S. Senate flips to the Democrats and former Vice President Joe Biden wins the presidency.

Read more
Illinois Marijuana Stores Have Now Sold More Than Half A Billion Dollars Worth Of Cannabis Products, State Announces

For the sixth month in a row, Illinois has hit yet another marijuana sales record, and it has reached the key benchmark of half a billion dollars worth of legal cannabis products being purchased since the launch of the program at the beginning of this year.

Read more
MindMed Has $50 Million In The Bank As It Looks Ahead To NASDAQ Uplisting

With an industry-leading psychedelic drug R&D portfolio, MindMed has plenty of options to leverage its cash-on-hand to a higher share price.

Read more
MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

This dosing study on LSD will be utilized as MindMed prepares for its Phase 2b clinical trial of LSD for anxiety.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )